FDA should tighten post-marketing surveillance of prescription drugs, says Institute of MedicineBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e3104 (Published 01 May 2012) Cite this as: BMJ 2012;344:e3104
- Bob Roehr
- 1Washington, DC
The US Food and Drug Administration (FDA) should look at the risk-benefit profile of approved drugs at pre-specified times after they are put on the market, the Institute of Medicine has recommended.
Its two year study, published on 1 May, grew out of a series of high profile controversies over drugs such as rosiglitazone for diabetes, rofecoxib for pain relief, and the cholesterol lowering drug rosuvastatin. It centres on enhanced regulatory authority given to the FDA in 2007 when Congress changed the law governing the agency.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial